Natixis Advisors L.P. has increased its stock holdings in Bio-Rad Laboratories. Despite currency troubles, Bio-Rad has seen gains due to its new product portfolio. Its Q1 2024 results beat EPS expectations but missed on revenue. Further investment was noted by Swiss National Bank, Retirement Systems of Alabama, Truist Financial Corp and Yousif Capital Management LLC. However, shares gapped down to $338.55 and declined further by 17.3% and 14%. The company advanced Global Sales and testing uptake but suffered due to biopharma softness and stiff competition. Cwm LLC and Fisher Asset Management LLC sold Bio-Rad stocks. Q1 earnings surpassed estimates, visions of sustainable innovation were maintained but margins went down. Bio-Rad's balance sheet remains healthy and they expect to post earnings soon. The past three years have proven unprofitable for Bio-Rad investors. However, investors' confidence in their revenues wavered. Despite declining sales, Bio-Rad maintains a full-year outlook. Oncocyte shares gained significantly due to a partnership with Bio-Rad. Significant insider sale was noted as EVP, Timothy Ernst sold 2500 shares. Bio-Rad's releases of Q4 earnings were anticipated with optimism but actual earnings fell short of estimates. A $500M share repurchase program was initiated. Newly appointed CFO is Roop K. Lakkaraju and the COO Andrew Last, announced retirement plans. A potential merger with the diagnostics firm Qiagen is rumored.
Bio-Rad Laboratories Stocks News Analytics from Thu, 21 Jan 2021 08:00:00 GMT to Fri, 10 May 2024 10:53:17 GMT -
Rating -3
- Innovation 3
- Information -1
- Rumor -5
